Beijing-based MegaRobo, which applies robotics and AI to life sciences research, has raised a ~$300M Series C led by GGV Capital and Asia Investment Capital
Coco Liu / Bloomberg :
Context & Ripple Effects
MegaRobo's ~$300M Series C lands mid-way through a decade-long escalation in Chinese robotics funding. The earlier wave was logistics-focused and far smaller: Roobo's $53M Series B in 2017 and Geek+'s $150M Series C1 in 2019 — the latter also led by GGV Capital, making this a repeat Beijing robotics bet by the same firm.
What changed by 2022 is both the check size and the application layer: MegaRobo points robotics and AI at life sciences research rather than warehouses. The rounds that follow in the coverage — Galbot raising over $300M at a $3B valuation and AI² Robotics at ~$736M — suggest MegaRobo's raise was an early marker of where the market was heading.
First-order effects
- MegaRobo gains roughly double the capital of GGV's previous Beijing robotics lead, Geek+, giving it the war chest to scale lab-automation deployments in life sciences.
- GGV Capital extends a thesis it first backed with Geek+: leading large Series C rounds for Beijing robotics companies, now joined by co-lead Asia Investment Capital.
Second-order effects
- Rivals chasing adjacent automation markets face a higher capital bar — the subsequent mega-rounds by Galbot (backed by China Mobile's industry investment fund) and AI² Robotics show later entrants needing state-linked or corporate money to compete at this level.
- Life sciences labs evaluating automation vendors now see a funded Chinese alternative alongside Western incumbents, pressuring pricing and partnership terms in lab robotics.
Third-order effects
- If the pattern holds, Chinese robotics consolidates around heavily capitalized platform companies spanning logistics, humanoids, and scientific automation, with the mix of financial VCs and state-affiliated funds (like China Mobile's) shaping who survives the scale-up phase.
- The decade-long climb from Roobo's $53M to nine-figure and billion-dollar-valuation rounds points to robotics being treated as strategic infrastructure rather than venture niche, drawing sovereign-adjacent capital into private rounds.
The trend: Chinese robotics funding has scaled from tens of millions to hundreds of millions per round over a decade, spreading from warehouse automation into humanoids and life sciences as state-linked capital joins traditional VCs.